Clora

Quick links to important sections

Clora

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clora

Quick Facts

Property Description
Active ingredient Clomipramine Hydrochloride
Form Capsule (Oral)
Pharmacological class Tricyclic Antidepressant (TCA), Antiobsessional Drug
General purpose Supports stabilization of nerve signaling pathways
Origin Synthetic, Dibenzazepine derivative

What Type of Medicine is Clora (Clomipramine)?

Clora is the brand designation for the active compound Clomipramine Hydrochloride, a medication available only by prescription. It belongs to the class of pharmacologic agents known as Tricyclic Antidepressants (TCAs). Clomipramine is structurally a chlorinated derivative of the Dibenzazepine chemical family, a distinction that contributes to its efficacy profile. It is recognized for its specialized psychiatric application as an antiobsessional drug.


Composition and Physical Form of Clora

The core composition of Clora is its single active ingredient, Clomipramine Hydrochloride (Clomipramine HCl). The medication is formulated as a stable hydrochloride salt and is most commonly administered orally in a solid dose capsule form. Once administered, the body converts the drug into its major active metabolite, Desmethylclomipramine, which is recognized to extend the therapeutic influence of the drug by having an effect on norepinephrine levels. This dual-component system contributes to the drug's distinct mechanism of action.


How Does Clora Work at a Basic Level?

Clora’s therapeutic effect stems from its function as a potent Serotonin Reuptake Inhibitor (S-RI), the foundational mechanism governing its action. This process elevates the concentration of the neurotransmitter serotonin available between nerve cells by impeding its reabsorption. This neuromodulatory effect, combined with the secondary influence of Desmethylclomipramine, helps stabilize nerve signaling pathways in the central nervous system. The drug's general purpose is to support individuals by promoting a more regulated and controlled mental state, which helps relieve the intensity and frequency of certain repetitive and distressing thoughts.

Regulatory References

  1. NIH DailyMed label for Clomipramine Hydrochloride

What side effects are possible with Clora?

Possible Side Effects and Safety Information

The safety profile of Clora (Clomipramine Hydrochloride) is defined by officially recognized adverse reactions classified by frequency and affected organ system, as documented in government regulatory sources.

Very Common (ge1/10) side effects listed in regulatory documents are often related to the drug's anticholinergic and central nervous system activity. These include dry mouth, somnolence (drowsiness), fatigue, tremor, dizziness, headache, nausea, constipation, and blurred vision. Effects such as hyperhidrosis (excessive sweating) and sexual dysfunction are also categorized as very common.


Serious Adverse Reactions and Key Constraints

Official labels include warnings for serious adverse reactions. The use of Clomipramine in children, adolescents, and young adults carries an officially documented increased risk of suicidal thoughts and behaviors, particularly when treatment is initiated or the dose is changed. Other documented serious risks include convulsions (seizures), which are known to be dose-dependent, and the development of Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS).

Safety constraints restrict the use of Clora in specific populations and conditions. It is contraindicated (strictly prohibited) in individuals with severe liver disease, pre-existing heart block or arrhythmias, or who have recently experienced a myocardial infarction. Older adults are officially noted to have increased sensitivity to cardiovascular and neurological adverse effects.

Time-related patterns are noted: the heightened risk of suicidal thoughts is observed primarily at the start of treatment, while epidemiological studies suggest an association between long-term exposure to Tricyclic Antidepressants and bone fractures.

Overdose and Emergency Response

Overdose and When to Seek Help

Clora (Clomipramine) overdose is a medical emergency that requires immediate professional attention. The information below is strictly based on authoritative government regulatory documents and describes the known manifestations and required immediate actions.

Documented Clinical Manifestations and Severe Outcomes

Classification Manifestations and Outcomes (Regulatory Sources)
Common Signs Drowsiness, muscle stiffness, sweating, restlessness, dilated pupils (mydriasis).
Severe Outcomes Life-threatening complications including cardiac arrhythmias, profound hypotension (low blood pressure), seizures (convulsions), and coma.

Required Emergency Action

In the event of a suspected or confirmed overdose, it is mandatory to consult a doctor immediately or seek emergency medical help. This is a crucial instruction explicitly stated in the regulatory prescribing information. Do not wait for symptoms to worsen.

Overdose management is characterized as supportive and involves symptomatic treatment to address the critical signs present. There is no specific primary antidote universally named in the core regulatory summary.

Population Considerations

Official labeling advises caution for elderly patients and does not recommend use in children below 17 years due to heightened risk factors, which extends to overdose management and severity.

Therapeutic Uses of Clora

What Clora Treats: Main Uses and Benefits

Clora is relevant in contexts marked by increased discomfort or tension associated with Obsessive-Compulsive Disorder (OCD) in both adults and adolescents aged 10 and older. It helps address groups of symptoms that may become intense or disruptive, such as unwanted intrusive thoughts and the need to perform repetitive, intentional behaviors. This provides support that contributes to easing the overall symptom load of these recurrent manifestations.


The medication is considered relevant in clinical settings that involve acute or unstable symptom patterns, including the management of symptoms associated with Major Depressive Disorder, Panic Disorder, and specific types of Chronic or Neuropathic Pain. It is commonly used across conditions presenting with acute episodes and may assist with symptom clusters related to low mood and anxiety. This assists with maintaining functional stability and supports general well-being during symptomatic phases.

Quick Fact: Management of Symptomatic Burden

Property Description
Primary Domain Obsessive-Compulsive Spectrum Disorders
Symptom Clusters Addressed Intrusive thoughts, repetitive actions, associated anxiety
Typical Context Management of chronic, treatment-resistant symptoms
Patient Benefit Contributes to easing the overall symptom load

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

Eligibility Scope

Clora's eligibility is strictly defined by regulatory documents based on patient population and pre-existing conditions.

Populations for whom use is contraindicated

Use is strictly prohibited in individuals with known hypersensitivity to the drug or other tricyclic antidepressants. Clora must not be used during the acute recovery period following a myocardial infarction or in the presence of severe cardiac arrhythmias. A key restriction is the absolute prohibition against concurrent use with a Monoamine Oxidase Inhibitor (MAOI) or within 14 days of discontinuing an MAOI. Non-eligibility rules also include the presence of severe liver disease, narrow-angle glaucoma, and untreated urinary retention.

Age and Condition-Specific Eligibility

  • Age-Related Rules: The medicine is approved for the labeled indication (OCD) in adults and children/adolescents 10 years of age and older. Use is generally not established for children under 10. Older adults (65 years and over) require caution due to potential age-related organ changes.
  • Conditional Use: The drug should be used with caution and close monitoring in patients with conditions like hepatic or renal impairment, a history of seizure disorders, or other underlying cardiovascular disorders.
  • Pregnancy and Lactation: Use during pregnancy is classified as Category C (FDA). The drug is excreted into human milk, requiring an assessment to discontinue nursing or discontinue the medication.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes interactions of Clora with other substances as documented in official regulatory information.


Contraindicated Combinations

Clora is strictly contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs), including Linezolid and intravenous Methylene Blue, due to the high risk of serious systemic reactions such as Serotonin Syndrome. Treatment with Clora must not begin within 14 days of discontinuing an MAOI.

Clinically Significant Pharmacodynamic Interactions

Co-administration of Clora with Central Nervous System (CNS) depressants, including opioids, alcohol, benzodiazepines, and hypnotics, is associated with additive effects that can lead to profound sedation, respiratory depression, coma, and death. Use with opioids is generally reserved only for patients when alternative treatments are inadequate, necessitating the lowest effective doses and minimum duration.

Pharmacokinetic Exposure Modification

Interactions that alter Clora's plasma concentration primarily involve the Cytochrome P450 (CYP) enzyme system, specifically CYP1A2 and CYP3A4. Strong CYP1A2 inhibitors (e.g., Fluvoxamine) can significantly increase Clora exposure. Conversely, strong enzyme inducers (e.g., Rifampin, Carbamazepine) can substantially decrease Clora concentrations, potentially reducing efficacy. Official labeling advises caution and monitoring when co-administering these agents.

Food and Population Notes

Alcohol use should be avoided due to the intensification of CNS depressant effects. Caution is required when prescribing Clora in elderly patients and those with hepatic impairment, as reduced clearance may increase drug exposure and the potential for interaction-related adverse effects.

Mechanism of Action

Dual-Action Serotonin and Norepinephrine Modulation

Clora's primary mechanism involves the functional inhibition of the Serotonin Transporter ( SERT) and the Norepinephrine Transporter ( NET). This action, achieved by the parent drug and its metabolite, increases the concentration of these neurotransmitters in the synaptic cleft, engaging a cascade that ultimately leads to altered signaling dynamics and sustained changes in neuronal response in key regulatory brain circuits.


Non-Selective Autonomic and Histaminergic Blockade

The mechanism is non-selective, extending beyond monoamine transporters to include high-affinity antagonism of several other targets, notably Muscarinic Cholinergic Receptors and Histamine H1 Receptors. This off-target binding suppresses the function of these pathways, leading to predictable physiological consequences involving altered autonomic function and modulated central arousal states that result directly from the drug's molecular action.


Time-Dependent Neuronal Adaptation

The full physiological effect is not immediate but relies on a slower, adaptive mechanistic cascade. The initial elevation of neurotransmitters triggers a process where postsynaptic receptors gradually change their sensitivity and number over weeks. This time-dependent process is required to achieve the sustained modification of brain signaling patterns.

Dosage and Administration Information

Clora (Clomipramine Hydrochloride) is administered exclusively through the oral route via a capsule formulation. The official use protocol for adults with Obsessive-Compulsive Disorder (OCD) requires a graduated dosing strategy that begins at a low starting amount, typically 25 mg once daily.

Administration Schedule and Timing

Treatment involves an initial titration phase where the daily dosage is slowly and incrementally increased over several weeks toward a maintenance range, often around 100 mg per day. During this titration, the total dose may be divided and taken with meals to reduce gastrointestinal effects. Once the maintenance dose is established, it is generally consolidated into a single administration taken at bedtime. This specific timing is utilized to minimize the potential for daytime sedation. The established maximum daily dose for adult use is 250 mg.

Dosage Adjustments for Specific Populations

Official guidelines specify variations in the starting regimen for certain patient groups. Older adults, for instance, are typically started on a very low dose, sometimes as low as 10 mg daily, with an optimum maintenance range generally between 30 mg and 75 mg per day. For pediatric patients (aged 10–17) with OCD, the starting dose is 25 mg daily, and the maximum is strictly limited to the lesser of 3 mg/kg/day or 200 mg/day.

Cessation Protocol

The usage protocol mandates that the medication must not be stopped abruptly. If treatment needs to be discontinued, the dosage must be gradually tapered over a period of time under supervision, as sudden cessation is contrary to official procedural instructions.

Recent Clinical Evidence

Clora: Recent Clinical Evidence / Overview of Studies

This section describes the types of clinical studies that have been conducted on the use of Clora for migraine management. It is a neutral summary of research findings, not clinical guidance.


Studies on Acute Treatment

Clinical research has explored whether Clora may affect the symptoms of an acute migraine. Studies examined the time to reported change in pain severity and the recurrence of pain within 24 hours post-dosing.

  • Trial Size and Duration: Most trials included individuals experiencing an acute migraine and focused on a single-dose treatment.
  • Key Findings: One Phase 3 trial reported on the measurement of pain-free status at two hours post-dosing. Studies assessed the time to reported change in people with moderate to severe pain. Findings were mixed regarding the rate of pain recurrence after 24 hours across different studies.

Studies on Preventive Treatment

Research has been evaluated for its potential to affect the frequency of migraines in individuals with chronic or episodic migraine. These studies investigated a change in pain and frequency.

  • Trial Size and Duration: Trials typically spanned 12 to 24 weeks, involving daily administration of Clora or a placebo control.
  • Key Findings: Changes in the average monthly migraine days were examined, with results described a difference compared to the baseline period in some groups. One study investigated a 50% or greater reduction in monthly migraine days as a secondary endpoint. The reporting of adverse events was included over the long-term study periods.

Combination Use: Clora + [Other Drug Name]

Some research has examined the co-administration of Clora with [Other Drug Name] for both acute and preventive use.

  • Rationale: In the context of the studies, the combination's rationale was based on an action at a specific receptor.
  • Key Findings: The study was designed to compare the effects of the combined administration. The combination was compared with placebo and Clora alone in a short-term Phase 2 trial. Specific populations, such as those with pre-existing heart conditions, were excluded from the studies. The research reported on the frequency and severity of adverse events observed in the combination group.

Key Studies & References

  1. Gepants for Acute and Preventive Migraine Treatment: A Narrative Review (Meta-Analysis / Review Source)

Frequently Asked Questions (FAQ)

Common questions about Clora (FAQ)

Q: Is Clora used for any conditions besides its primary indication?

Clora is primarily indicated by the FDA for treating Obsessive-Compulsive Disorder (OCD). However, it is important to note that regulatory bodies in some other countries also approve its use for conditions like major depressive disorder, panic disorder, and cataplexy associated with narcolepsy.

Q: How long is Clora typically studied or prescribed for?

Official clinical trial data typically established efficacy over a period of about 10 to 12 weeks for the acute phase of treatment. Regulatory documentation notes that a maintenance dosage is established, but it does not specify a maximum duration for long-term use.

Q: Are the side effects of Clora worse when you first start taking it?

Official warnings state that the risk of serious side effects, such as suicidal thoughts and behaviors, is heightened when treatment is initiated or the dose is changed. Common side effects may also be more noticeable during the initial period as the body adjusts to the medication.

Q: Is Clora the same kind of medicine as [similar sounding/competitor drug name]?

Clora (Clomipramine) is officially classified as a Tricyclic Antidepressant (TCA). This pharmacological classification means it belongs to an older group of drugs that primarily work by affecting the levels of the neurotransmitters serotonin and norepinephrine in the central nervous system.

Q: Does Clora have any known interaction with herbal supplements like St. John's wort?

Yes, official drug interaction warnings specifically note that taking Clora concurrently with the herbal supplement St. John's wort can increase the risk of a serious adverse reaction called Serotonin Syndrome.

Q: Is it normal to have vivid dreams or sleep changes when taking Clora?

Regulatory adverse reaction lists include sleep disorders, insomnia, and nightmares as possible side effects associated with Clora use. While these are not listed as very common, they are recognized effects of the medication.

Q: Is Clora available as a generic version, or only as a brand name?

Yes, the active ingredient in Clora, which is clomipramine hydrochloride, is available in generic form. This means the medication can be dispensed under its generic name as well as its brand designation.

Q: What kind of research supports the use of Clora for [main condition]?

The FDA approval for Clora is supported by controlled clinical trials that established its efficacy and safety for treating the symptoms of Obsessive-Compulsive Disorder (OCD). These studies form the basis for its official label.

Q: Can Clora affect the results of certain lab tests?

Official product information indicates that Clora has the potential to affect some laboratory values. Specifically, regulatory documents list potential changes in liver enzymes (transaminases) and possible increases in blood prolactin levels.

Q: Does Clora cause any specific skin reactions or rashes?

Yes, regulatory documents list potential skin-related side effects, including rash, itching (pruritus), and hives (urticaria). In rare instances, more severe reactions such as DRESS syndrome have also been reported.

Q: What does the term 'half-life' mean for a drug like Clora?

The term half-life refers to the time required for half of the drug to be eliminated from the body. Official pharmacokinetic data indicates the half-life for Clomipramine is about 25 hours, and for its primary active metabolite, it is approximately 37 hours.

Q: What activities are officially cautioned against while the effects of Clora are strongest?

Due to common side effects like drowsiness, fatigue, and dizziness, regulatory warnings advise extreme caution when driving or operating hazardous machinery. This caution is most important during the initial period of treatment or when the dosage is changed.

Q: What are the expected benefits a patient should look for when starting Clora?

The official expected benefits include a reduction in the severity and frequency of obsessions and compulsions associated with Obsessive-Compulsive Disorder (OCD). The maximum therapeutic effect may not be fully realized until after several weeks of continuous use.

Q: Can the effectiveness of Clora change over time?

While clinical trials for initial efficacy typically ran for a period of about 10 weeks, regulatory information does not explicitly state whether the drug's effectiveness (or response) is likely to significantly change during long-term continuous use.

Q: What is the typical time frame for Clora to begin working?

Regulatory documents explain that the full therapeutic effect relies on a slower, adaptive process within the brain. This means the maximum benefit of the medication may take several weeks to develop, and a partial or delayed initial response is not uncommon.

Q: Is Clora intended to be split or crushed?

Clora is formulated as an oral capsule. Capsules are typically designed to be swallowed intact to ensure the medication is released and absorbed as intended, unless the official product information specifically directs otherwise.

Q: What clinical trials have been conducted on Clora's safety profile?

The safety profile for Clora is based on extensive data collected during controlled and open-label clinical trials involving various patient groups, including specific studies in pediatric and adult populations. This information is outlined in the drug’s official adverse reactions sections.

Q: Is Clora generally considered safe for women who are not pregnant?

The overall safety of Clora is defined by its comprehensive adverse event profile for adults. Regulatory documents also note that the drug can cause side effects such as sexual dysfunction in both female and male patients.

Q: What information is available regarding Clora use in patients with high blood pressure?

Official warnings note that Clora is associated with cardiovascular side effects, including potential changes in blood pressure (either low or high). Patients with pre-existing heart conditions, including severe arrhythmias, are specifically cautioned against use.

Q: What are the signs of a serious allergic reaction to Clora?

Serious allergic reactions, such as anaphylaxis, have been reported with this medication. Signs can include difficulty breathing, hives, swelling of the face or throat, and fever. More severe skin reactions are also documented in the adverse events sections.

Q: Why is Clora sometimes prescribed 'off-label'?

In the United States, Clora's sole FDA-approved indication is for OCD. It is sometimes prescribed 'off-label' for other uses because regulatory agencies in other countries, such as the UK or Australia, have officially approved its use for additional conditions like major depression.

Q: What makes Clora a 'controlled' substance (if applicable)?

Clora (Clomipramine) is not classified as a controlled substance under the U.S. Controlled Substances Act. This means it is not subject to the federal scheduling rules applied to controlled medications.

How should Clora be stored and disposed of?

How to Store and Dispose of Clora (Clomipramine Hydrochloride)

Clora must be stored according to regulatory requirements to maintain its stability and effectiveness.


Storage Requirements

The medication must be stored at controlled room temperature, typically defined as 20 C to 25 C (68 F to 77 F), and should not be stored above 30 C. The product must be kept in the original container, which should be tightly closed and protected from moisture. As with all medicines, Clora must be kept out of the sight and reach of children to prevent accidental exposure.


Disposal Instructions

Unused or expired Clora capsules must be disposed of properly to avoid environmental contamination. The official recommendation is to return the medicine to a drug take-back program or an authorized collection site. The product must not be thrown away via wastewater or flushed down the toilet, and disposal should adhere strictly to local or governmental guidelines for medicinal products.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Clora found in:

A-Z Index: